EVIDENCE-BASED THERAPY TO REDUCE LIFE-THREATENING CARDIOVASCULAR EVENTS Company Overview NASDAQ: AMRN FEBRUARY 2026 Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (icosapent ethyl) (VAZKEPA® in Europe and in other territories), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, research and development, intellectual property and liti ...

Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge Supported in 2025 DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDA ...

Financial Performance - Amarin Corporation plc reported a year-end 2025 cash balance of $303 million, reflecting a growth of $16 million compared to $287 million in Q3 2025 [3] - The company expects its fiscal Q4 2025 net revenue to be in the range of $48 to $53 million, with fiscal year 2025 net revenue projected to be between $212 to $217 million [3] Operational Highlights - The company achieved positive cash flow in fiscal Q4 2025 earlier than previously forecasted, driven by a significant reduction in operating expenses and a long-term partnership with Recordati S.p.A. to commercialize VAZKEPA® across 59 countries, focusing on Europe [1] - Amarin believes it is on track for sustainable positive annual cash flow in 2026, supported by a full year of cost savings from its restructuring plan, with most expenses related to the plan already incurred in 2025 [2] Company Overview - Amarin Corporation plc is a pharmaceutical company focused on the development and commercialization of therapeutics targeting cardiovascular health, specifically developing and commercializing Vascepa capsules [4]

Financial Performance - Total revenue for Q1 2025 was $42.0 million[14, 21] - U S revenue was $35.7 million, a ~26% year-over-year reduction[21] - Europe revenue was $5.4 million, a ~284% year-over-year increase[14, 21] - Operating expenses for Q1 2025 were $41.9 million, an 8% reduction year-over-year[14, 19] - The company maintained a strong cash position with $281.8 million and no debt[14, 24] Business Updates - Achieved sequential growth in in-market demand across all European markets where VAZKEPA was launched, particularly in Spain, the UK, and CEE[13] - Secured pricing and reimbursement in Austria and continued progress in other EU markets[13] - CSL's efforts led to VAZKEPA's inclusion in the National Heart Foundation/Cardiac Society Acute Coronary Syndrome guidelines in Australia[13] - Edding continued CVRR launch in the private pay market in China, working towards National Reimbursement Drug List (NRDL) review for 2026[13] Strategic Priorities - Drive growth in access and revenue in Europe and Rest of World markets[30] - Drive efficient VASCEPA U S revenue generation[30] - Support research that reinforces VASCEPA science and therapeutic value[30] - Maintain fiscal and operational discipline while pursuing all avenues to maximize shareholder value[30]